Hiroyoshi Takeuchi, MD, PhD

  • 14Articles
  • 76.9KReads
  • 2010–2025Active
  • 46Collaborators
  • 161Citations

About

Hiroyoshi Takeuchi, MD, PhD, is affiliated with the Department of Neuropsychiatry at Keio University School of Medicine in Tokyo, Japan. Since 2010, Takeuchi has published extensively on topics including schizophrenia, schizoaffective disorders, delirium, geriatric psychiatry, mood disorders, movement disorders, psychopharmacology, and psychotic disorders. His work encompasses clinical and pharmacological studies such as antipsychotic dosing regimens, long-acting injectable treatments, and pharmacokinetic analyses. Takeuchi has contributed to research on both patient- and clinician-rated illness severity and the effects of various antipsychotic medications.

Publications

JCP
IV Hydroxyzine vs Haloperidol for Delirium
Original Research

IV Hydroxyzine vs Haloperidol for Delirium

January 6, 2025

Hydroxyzine showed a significantly higher rate of delirium improvement than haloperidol, with no significant difference in the time to improvement.
, , , et al
JCP
Does the Onset of Efficacy for Agitation Vary Depending on the Administration Route of Antipsychotics?
Letter to the Editor

Does the Onset of Efficacy for Agitation Vary Depending on the Administration Route of Antipsychotics?

March 20, 2024

As choice of administration route is crucial during psychiatric emergencies, the authors stress the need for RCTs comparing onset of efficacy for agitation across different administration routes of the...
,
JCP
Tardive Dyskinesia and Long-Acting Injectable Antipsychotics
Original Research

Tardive Dyskinesia and Long-Acting Injectable Antipsychotics

August 3, 2022

This study compared spontaneous reporting of tardive dyskinesia with long-acting injectable versus oral antipsychotics.
, ,
JCP
Meta-Analysis

Single vs Multiple Dose Regimens of Psychotropic Drugs

February 23, 2021

Single-daily-dose regimens are easier for patients to follow than multiple-dose regimens and may increase adherence. But do they work as well? And are they safe? Read this meta-analysis to...
, , , et al
JCP
Original Research

Effects of LAI Paliperidone Based on Illness Duration

January 12, 2021

Although long-acting injectable (LAI) antipsychotics show benefit in the early stages of schizophrenia, they are mostly used later in the illness. This study assessed clinical and functional improvement with...
, , , et al
JCP
Review Article

Central and Peripheral Pharmacokinetics of Antipsychotics

July 28, 2020

Pharmacokinetics of antipsychotics are generally slower centrally than peripherally. This review examined the possible dissociation between central D2 receptor occupancy with antipsychotics and their peripheral blood concentrations.
, , , et al
JCP
Meta-Analysis

Aripiprazole and Worsening Psychosis

March 6, 2018

Case reports suggest psychosis might worsen with a switch to or addition of aripiprazole. But is worsening just as likely with other antipsychotics? To answer this question, this government-supported...
, , , et al
JCP
Article

Two Strategies for Switching to Clozapine

February 22, 2017

What's the best way to switch to clozapine in patients with treatment-resistant schizophrenia? Do you worry that efficacy and tolerability will be compromised? This pilot, double-blind RCT addresses your...
, , , et al
JCP
Article

Quantifying Intraindividual Variations in Plasma Clozapine Levels: A Population Pharmacokinetic Approach

May 25, 2016

Clozapine is the most effective antipsychotic used in the treatment of refractory schizophrenia. But how do factors like smoking and caffeine intake affect plasma clozapine levels? The authors of...
, , , et al
JCP
Original Research

Determinants of Patient-Rated and Clinician-Rated Illness Severity in Schizophrenia

July 22, 2015

, , , et al
JCP
Original Research

Dose Reduction of Risperidone and Olanzapine and Estimated Dopamine D2 Receptor Occupancy in Stable Patients With Schizophrenia: Findings From an Open-Label, Randomized, Controlled Study

July 22, 2014

, , , et al
JCP
Original Research

Impact of Once- Versus Twice-Daily Perphenazine Dosing on Clinical Outcomes: An Analysis of the CATIE Data

May 15, 2014

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe